Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial

Reuters12-12

<a href="https://laohu8.com/S/RLAY">Relay Therapeutics</a> Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial

Relay Therapeutics Inc. announced interim clinical data from a subset analysis of the investigational drug zovegalisib (RLY-2608), an allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα, in combination with fulvestrant for patients with PI3Kα-mutated, HR+/HER2- advanced breast cancer previously treated with CDK4/6 inhibitors. The data were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Efficacy results showed a median progression-free survival $(PFS)$ of 10.3 months in all patients and 11.4 months in second-line patients, with activity observed across subgroups regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status. The ongoing Phase 3 ReDiscover-2 trial continues to enroll CDK4/6-experienced breast cancer patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600940-en) on December 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590055745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590055745","market":"fut","top_or_hot":-1,"title":"Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced interim clinical data from a subset analysis of the investigational drug zovegalisib (RLY-2608), an allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα, in combination with fulvestrant for patients with PI3Kα-mutated, HR+/HER2- advanced breast cancer previously treated with CDK4/6 inhibitors. The data were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Efficacy results showed a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 10.3 months in all patients and 11.4 months in second-line patients, with activity observed across subgroups regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status. The ongoing Phase 3 ReDiscover-2 trial continues to enroll CDK4/6-experienced breast cancer patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600940-en) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced interim clinical data from a subset analysis of the investigational drug zovegalisib (RLY-2608), an allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα, in combination with fulvestrant for patients with PI3Kα-mutated, HR+/HER2- advanced breast cancer previously treated with CDK4/6 inhibitors. The data were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Efficacy results showed a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 10.3 months in all patients and 11.4 months in second-line patients, with activity observed across subgroups regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status. The ongoing Phase 3 ReDiscover-2 trial continues to enroll CDK4/6-experienced breast cancer patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600940-en) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL5sv1QF:1","article_id":"2590055745","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590055745","pubTimestamp":1765540820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Relay Therapeutics Inc. announced interim clinical data from a subset analysis of the investigational drug zovegalisib , an allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα, in combination with fulvestrant for patients with PI3Kα-mutated, HR+/HER2- advanced breast cancer previously treated with CDK4/6 inhibitors. The data were presented at the 2025 San Antonio Breast Cancer Symposium . Efficacy results showed a median progression-free survival  of 10.3 months in all patients and 11.4 months in second-line patients, with activity observed across subgroups regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status. The ongoing Phase 3 ReDiscover-2 trial continues to enroll CDK4/6-experienced breast cancer patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4588":"碎股","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4563":"昨日强势股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","RLAY":"Relay Therapeutics","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Relay Therapeutics报告Zovegalisib在乳腺癌3期试验中取得有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RLAY":0.9},"content_text":"Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial\n    \n\n        Relay Therapeutics Inc. announced interim clinical data from a subset analysis of the investigational drug zovegalisib (RLY-2608), an allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα, in combination with fulvestrant for patients with PI3Kα-mutated, HR+/HER2- advanced breast cancer previously treated with CDK4/6 inhibitors. The data were presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Efficacy results showed a median progression-free survival $(PFS)$ of 10.3 months in all patients and 11.4 months in second-line patients, with activity observed across subgroups regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status. The ongoing Phase 3 ReDiscover-2 trial continues to enroll CDK4/6-experienced breast cancer patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600940-en) on December 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590055745","isCrawlerRequest":true}